【摘要】：目的觀察甲潑尼龍片聯(lián)合嗎替麥考酚酯膠囊治療急性腎損傷的臨床療效和安全性。方法將72例急性腎損傷患者隨機(jī)分為對(duì)照組36例和試驗(yàn)組36例。對(duì)照組予以口服嗎替麥考酚酯,每次500 mg,bid,每療程2周,連續(xù)治療2個(gè)療程;試驗(yàn)組在對(duì)照組的基礎(chǔ)上予以口服甲潑尼龍,每次4 mg,tid,每療程2周,連續(xù)治療2個(gè)療程。比較2組患者的臨床療效、治療后3,7,15 d尿素氮(BUN)、血肌酸酐(Scr)及Notch蛋白的表達(dá)情況,以及藥物不良反應(yīng)發(fā)生率。結(jié)果治療后,對(duì)照組和試驗(yàn)組的總有效率分別為69.44%(25/36例)和88.89%(32/36例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療3,7,15 d后,試驗(yàn)組和對(duì)照組BUN、Scr含量Notch蛋白指標(biāo)明顯低于治療前;治療后,試驗(yàn)組和對(duì)照組的血紅蛋白指標(biāo)分別為(123.46±10.36),(101.37±12.24)g·L~(-1),KIM~(-1)分別為(0.34±0.12),(0.93±0.39)ng·m L~(-1),SOD分別為(72.24±7.26),(84.86±9.71)U·m L~(-1),MDA分別為(4.05±0.51),(5.36±0.79)nmol·m L~(-1),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。試驗(yàn)組的藥物不良反應(yīng)主要有肝功能異常1例,感染1例,高血壓1例;對(duì)照組的藥物不良反應(yīng)主要有肝功能異常1例,感染2例,高血壓1例。試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為8.33%(3/36例)和11.11%(4/36例),差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論甲潑尼龍聯(lián)合嗎替麥考酚酯比單一使用嗎替麥考酚酯治療急性腎損傷臨床療效更佳,提高Notch蛋白的表達(dá)量,利于建立Notch/Hes1信號(hào)通路的,促進(jìn)恢復(fù)血清細(xì)胞因子。
[Abstract]:Objective to observe the clinical efficacy and safety of methylprednisolone tablets combined with metocophenolate capsules in the treatment of acute renal injury. Methods 72 patients with acute renal injury were randomly divided into control group (n = 36) and experimental group (n = 36). The control group was given oral metocophenolate motifen for 2 weeks and the control group was given methylprednisolone 4 mg / tid for 2 weeks for 2 consecutive courses of treatment. The clinical efficacy, urea nitrogen (bun), serum creatinine (SCR), Notch protein expression and adverse drug reaction (ADR) were compared between the two groups. Results after treatment, the total effective rates of the control group and the experimental group were 69.44% (25 / 36 cases) and 88.89% (32 / 36 cases), respectively. The difference was statistically significant (P0.05). 娌葷枟3,7,15 d鍚，

本文編號(hào)：2134954